Engineered CasX Repressor Systems, EP4405479A2

EPO published patent application EP4405479A2 for engineered CasX repressor systems developed by Scribe Therapeutics Inc., covering a novel class of programmable DNA-binding proteins for gene expression modulation. The six inventors are Fernandes, White, Higgins, Denny, Oakes, and Charles. The application is classified under C12N 15/113 and C12N 9/22 relating to nucleic acid technology and enzymes.

For entities in biotechnology and pharmaceutical research, this patent publication establishes intellectual property protection for CasX repressor technology across European markets. Companies developing CRISPR-based gene editing tools or therapeutic programs should review this publication for potential freedom-to-operate implications or licensing opportunities. The designated states include all EU member states plus Switzerland, Norway, and other EPC contracting states.